Dr Lal Pathlabs Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹660Cr
- +10.6% YoY
- −9.7% QoQ
- Net profit
- ₹91Cr
- −7.1% YoY
- −40.1% QoQ
- Margin
- 27%
- +1 pp YoY
- −4 pp QoQ
Guidance rank: #24 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
The company targets organic revenue growth of 11%-12% for the current financial year, aiming to improve this baseline going forward. The company aims for organic revenue growth of 11%-12% for the current financial year, with aspirations to improve beyond this baseline in the medium term.
From Dr Lal Pathlabs Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets organic revenue growth of 11%-12% for the current financial year, aiming to improve this baseline going forward.
- Patient volume growth has shown a steady increase from a low base, with expectations of slow and steady improvement rather than sudden jumps.
- Expansion in newer markets including Tier 2, Tier 3, and rural towns will drive volume growth by increasing geographic spread and patient access.
- The Swasthfit preventive health testing model is scaling well into smaller towns, contributing to incremental volumes without cannibalizing margins.
- Inorganic growth opportunities are being pursued selectively, particularly larger acquisitions in South markets and standalone labs in smaller regions, adding to volume and revenue.
2 more points from Dr Lal Pathlabs Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Dr Lal Pathlabs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- For FY26, capex is estimated around Rs. 150-160 crore, higher than the usual Rs. 50-70 crore, due to investments in radiology centers and the new Sovaaka preventive wellness program.
- Radiology centers require significant investment; one center costs about Rs. 15-16 crore. Plans include opening 1 or 2 more advanced radiology centers.
- The typical sustainable capex going forward may settle around Rs. 60-70 crore operational capex plus about Rs. 30-40 crore for 2 radiology centers, totaling approximately Rs. 100-110 crore annually.
- Additional investments may arise from new initiatives or expansions beyond current plans.
2 more points from Dr Lal Pathlabs Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dr Lal Pathlabs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Dr Lal Pathlabs Ltd — Quarterly revenue & net profit
Dr Lal Pathlabs Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 660 | 597 | +10.6% | 731 | -9.7% |
| Operating profit (EBITDA) | 179 | 154 | +16.2% | 224 | -20.1% |
| Operating margin | 27% | 26% | +1 pp | 31% | -4 pp |
| Profit before tax | 124 | 138 | -10.1% | 204 | -39.2% |
| Net profit (PAT) | 91 | 98 | -7.1% | 152 | -40.1% |
| EPS (₹) | 5.40 | 5.78 | -6.6% | 8.99 | -39.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹874 Cr, net profit ₹194 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Lal Pathlabs's management said in earlier quarters
Others in Healthcare Services this season
- Vijaya Diagnostic Centre (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —
- Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthca (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Childrens Medicare (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Dr Lal Pathlabs Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dr Lal Pathlabs Ltd Q3 FY26 results?
The company targets organic revenue growth of 11%-12% for the current financial year, aiming to improve this baseline going forward. The company aims for organic revenue growth of 11%-12% for the current financial year, with aspirations to improve beyond this baseline in the medium term.
What is Dr Lal Pathlabs Ltd share price analysis?
Dr Lal Pathlabs Ltd currently shows a neutral. The stock trades at a P/E of 56.3 with a market cap of ₹31,635 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Lal Pathlabs Ltd planning capital expenditure?
For FY26, capex is estimated around Rs. 150-160 crore, higher than the usual Rs. 50-70 crore, due to investments in radiology centers and the new Sovaaka preventive wellness program.
Keep Dr Lal Pathlabs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
